Viktor Rokutov, MD
Dnipro City Central Hospital
Dnipro, Ukraine 2018
The purpose of this investigation was to evaluate the ability of Progeneron Hand Cream to treat
symptoms of Dupuytren’s Disease and collect safety and tolerance information.
MATERIALS AND METHODS
Five patients with various stages of Dupuytren’s Disease were recruited and are being treated with
Progeneron Hand Cream. Initial parameters were assessed on entry and every week thereafter. Pain,
adverse effects and medical and subject assessment scores are being collected on a weekly basis until
week 8, after which scores are being collected by‐weekly.
After 12 weeks of tests Progeneron Hand Cream had no deleterious effects on skin condition, blood or
liver function, or any other significant side‐effects. Discomfort associated with hand activity, medical
and patient assessment scores were all significantly reduced, with benefits occurring within the first
few weeks of therapy. Cords were not significantly affected, however the range of passive and active
motion of the affected fingers was extended significantly. Hardened surfaces in the palm of the hand